Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $268.0 million.

  • Beam Therapeutics' Cash & Equivalents rose 1640.16% to $268.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $268.0 million, marking a year-over-year increase of 1640.16%. This contributed to the annual value of $282.0 million for FY2024, which is 3531.31% down from last year.
  • As of Q3 2025, Beam Therapeutics' Cash & Equivalents stood at $268.0 million, which was up 1640.16% from $282.1 million recorded in Q2 2025.
  • Beam Therapeutics' Cash & Equivalents' 5-year high stood at $612.0 million during Q3 2021, with a 5-year trough of $97.2 million in Q1 2021.
  • Its 5-year average for Cash & Equivalents is $299.2 million, with a median of $268.0 million in 2025.
  • Per our database at Business Quant, Beam Therapeutics' Cash & Equivalents surged by 34380.69% in 2021 and then tumbled by 7442.73% in 2022.
  • Over the past 5 years, Beam Therapeutics' Cash & Equivalents (Quarter) stood at $560.0 million in 2021, then plummeted by 58.43% to $232.8 million in 2022, then soared by 87.27% to $435.9 million in 2023, then tumbled by 35.31% to $282.0 million in 2024, then decreased by 4.97% to $268.0 million in 2025.
  • Its Cash & Equivalents was $268.0 million in Q3 2025, compared to $282.1 million in Q2 2025 and $527.9 million in Q1 2025.